Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

INGN-225 to be studied for advanced breast cancer in phase I/II trial

Dec. 11, 2003

Interim results from phase II studies of HuMax-CD4 for CTCL

Dec. 11, 2003

Encouraging outcomes for Rituxan phase II and III trials

Dec. 11, 2003

hTERT-based vaccine approaches to breast cancer

Dec. 10, 2003

MLN-2704 granted fast track designation

Dec. 9, 2003

Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo

Dec. 9, 2003

Cetuximab enhances antitumor effects of cisplatin in late-stage clinical trial

Nov. 27, 2003

Medarex given go-ahead to begin phase I/II trial of MDX-214

Nov. 26, 2003

FDA lifts partial clinical hold on phase III trials of Oncophage

Nov. 26, 2003

Shionogi describes GM-CSF-like compounds with potential in cancer and neutropenia

Nov. 25, 2003

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...